NasdaqCM:PAVM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$546.0m

Last Updated

2021/06/23 00:52 UTC

Data Sources

Company Financials +

Executive Summary

PAVmed Inc. operates as a medical device company in the United States. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has PAVmed's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PAVM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: PAVM's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

7.4%

PAVM

2.7%

US Medical Equipment

-0.1%

US Market


1 Year Return

181.8%

PAVM

35.7%

US Medical Equipment

39.0%

US Market

Return vs Industry: PAVM exceeded the US Medical Equipment industry which returned 35.7% over the past year.

Return vs Market: PAVM exceeded the US Market which returned 39% over the past year.


Shareholder returns

PAVMIndustryMarket
7 Day7.4%2.7%-0.1%
30 Day41.8%3.9%2.6%
90 Day61.1%10.9%8.0%
1 Year181.8%181.8%36.7%35.7%41.2%39.0%
3 Year560.9%560.9%69.2%65.3%62.4%52.3%
5 Yearn/a161.1%142.3%132.3%106.2%

Long-Term Price Volatility Vs. Market

How volatile is PAVmed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PAVmed undervalued compared to its fair value and its price relative to the market?

11.11x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PAVM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PAVM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PAVM is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: PAVM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PAVM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PAVM is overvalued based on its PB Ratio (11.1x) compared to the US Medical Equipment industry average (4.7x).


Future Growth

How is PAVmed forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

12.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PAVM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PAVM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PAVM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if PAVM's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if PAVM's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PAVM's Return on Equity is forecast to be high in 3 years time


Past Performance

How has PAVmed performed over the past 5 years?

-37.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PAVM is currently unprofitable.

Growing Profit Margin: PAVM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PAVM is unprofitable, and losses have increased over the past 5 years at a rate of 37.7% per year.

Accelerating Growth: Unable to compare PAVM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PAVM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.1%).


Return on Equity

High ROE: PAVM has a negative Return on Equity (-64.71%), as it is currently unprofitable.


Financial Health

How is PAVmed's financial position?


Financial Position Analysis

Short Term Liabilities: PAVM's short term assets ($50.5M) exceed its short term liabilities ($3.3M).

Long Term Liabilities: PAVM has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: PAVM's debt to equity ratio (0.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if PAVM's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PAVM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PAVM has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 39.8% each year.


Dividend

What is PAVmed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PAVM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PAVM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PAVM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PAVM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PAVM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Lishan Aklog (54 yo)

7yrs

Tenure

US$1,196,300

Compensation

Dr. Lishan Aklog, M.D, serves as Director at ContraFect Corporation since June 14, 2020. Dr. Aklog has also served as Executive Chairman of Lucid Diagnostics Inc. since its inception in 2018. Dr. Aklog ser...


CEO Compensation Analysis

Compensation vs Market: Lishan's total compensation ($USD1.20M) is about average for companies of similar size in the US market ($USD1.67M).

Compensation vs Earnings: Lishan's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PAVM's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: PAVM's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 76.7%.


Top Shareholders

Company Information

PAVmed Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PAVmed Inc.
  • Ticker: PAVM
  • Exchange: NasdaqCM
  • Founded: 2014
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$545.988m
  • Shares outstanding: 83.87m
  • Website: https://www.pavmed.com

Number of Employees


Location

  • PAVmed Inc.
  • One Grand Central Place
  • Suite 4600
  • New York
  • New York
  • 10165
  • United States

Listings


Biography

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell col...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/23 00:52
End of Day Share Price2021/06/22 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.